Media-OutReach Newswire Abivax receives ANSM and Ethics Committee clearance to test its development candidate ABX464 in 1,034 Covid-19 patients in randomized Phase 2b/3 clinical trial
Media-OutReach Newswire Vetter's High Performance is Again Recognized at the 2020 CMO Leadership Awards